Published in Medical Letter on the CDC and FDA, January 11th, 2009
The company also announced that it has initiated safety and toxicity trials for the first Oxycyte wound-treatment indication.
In action items following the company’s meeting with the FDA on Oct. 22, 2008, the agency requested further information and data about thrombocytopenia – low...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA